Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Med Interne ; 45(1): 17-25, 2024 Jan.
Article in French | MEDLINE | ID: mdl-37838484

ABSTRACT

Splanchnic vein thrombosis includes Budd-Chiari syndrome and portal vein thrombosis. These diseases share common features: (i) they are rare diseases and (ii) they can lead to portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, the most common being myeloproliferative neoplasms. A rapid and comprehensive workup for thrombosis risk factors is necessary in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis, and is associated with a worse course of cirrhosis. Indications for anticoagulation in patients with cirrhosis are increasing. Transjugular intrahepatic portosystemic shunt is a second-line procedure in this setting. Because of the rarity of these diseases, high-level evidence studies are rare. However, collaborative studies have provided a better understanding of their natural history and allowed to improve the management of these patients. This review focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, patients with portal vein thrombosis without underlying liver disease, and patients with cirrhosis and portal vein thrombosis.


Subject(s)
Budd-Chiari Syndrome , Portasystemic Shunt, Transjugular Intrahepatic , Thrombosis , Venous Thrombosis , Humans , Budd-Chiari Syndrome/diagnosis , Budd-Chiari Syndrome/epidemiology , Budd-Chiari Syndrome/etiology , Portal Vein , Venous Thrombosis/complications , Venous Thrombosis/diagnosis , Venous Thrombosis/epidemiology , Thrombosis/complications , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Anticoagulants/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...